Targeted radioactive therapy may help delay spread of recurrent prostate cancer
Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Light-activated cotton fabric reduces harmful microorganisms in hospital rooms
United Kingdom
-
Ketamine relieves pain without 'disconnecting' consciousness, study finds
United Kingdom
-
New paper outlines growing role of interventional radiology in liver cancer treatment
United Kingdom
-
Single-cell analysis reveals how pancreatic cancer evades treatment
United Kingdom
-
Switching to a vegan diet rapidly alters liver metabolism
United Kingdom
-
New AI tool detects early psychosis risk in youth speech
United Kingdom
-
A handful of walnuts a day may make your diet less inflammatory
United Kingdom
-
General dietary interventions may matter more than specific habits before bariatric surgery, study shows
United Kingdom